How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

804 results for

aspirin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. The use of salicylic acid in a new delivery system as a co-adjuvant topical treatment for acne vulgaris. Full Text available with Trip Pro

The use of salicylic acid in a new delivery system as a co-adjuvant topical treatment for acne vulgaris. Topical preparations in the form of creams or ointments are the usual treatment for acne. These agents do not seem to penetrate the skin barrier deeply enough to produce the desired effect.We conducted a randomized, double-blinded, prospective study to evaluate the effectiveness of salicylic acid in a new delivery system, the Crown Carrier System (CCS, Trivitaderm LLC, Asheville, NC (...) ) for the treatment of acne.Thirty-seven patients with homogenous backgrounds were randomly divided into 3 groups. Group A was treated with salicylic acid in CCS, Group B was treated with CCS without salicylic acid, and Group C received salicylic acid alone. Patients were evaluated at 2 weeks and 8 weeks post-treatment.Twenty-five patients completed the evaluation. Most patients in Group A presented with no changes in the number of acne lesions but with significant improvement of inflammatory signs. Their overall

2009 Aesthetic surgery journal Controlled trial quality: uncertain

62. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Full Text available with Trip Pro

Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the live-birth rate in subsequent pregnancies in women with either inherited thrombophilia or unexplained recurrent miscarriage.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without (...) in women with a history of at least two miscarriages (up to 20 weeks of amenorrhoea) without apparent causes other than inherited thrombophilia were eligible. Interventions included aspirin, unfractionated heparin, and low molecular weight heparin for the prevention of miscarriage. One treatment could be compared with another or with placebo.Two authors assessed the trials for inclusion in the review and extracted the data. We double checked the data.Two studies (189 participants) were included

2009 Cochrane

63. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

64. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

65. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis

Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

66. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

67. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials

The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

68. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

69. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force

Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Wolff T, Miller T, Ko S Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 68. 2009 Authors' objectives To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions

2009 Health Technology Assessment (HTA) Database.

70. COVID-19 and Pregnant Patients

anatomical ultrasound 28 weeks gestation for routine labs and vaccinations 32 weeks gestation for ultrasound if clinically indicated 36 weeks gestation for ultrasound if clinically indicated and group-B streptococcus and HIV screening 37 weeks gestation until delivery for weekly assessments Reference - American College of Obstetricians and Gynecologists (ACOG) recommends that low-dose aspirin continue to be offered to pregnant and postpartum women with suspected or confirmed COVID-19 as medically

2020 DynaMed Plus

71. COVID-19 and Cardiovascular Disease Patients

or hypertension should continue medications in patients with confirmed or suspected COVID-19, do not stop ACE inhibitor, ARB, or ARNI unless indicated (such as in case of symptomatic hypotension, shock, acute kidney injury, or hyperkalemia) Reference - Acetaminophen and aspirin Canadian Cardiovascular Society (CCS) guidance in patients who take low-dose aspirin for heart disease continue therapy confirmation or suspicion of COVID-19 not considered indication to stop aspirin consider acetaminophen instead (...) Association for Respiratory Care/American College of Emergency Physicians/Society of Critical Care Anesthesiologists/American Society of Anesthesiologists (AHA/AAP/AARC/ACEP/SCCA/ASA) interim guidance on basic and advanced life support in adults, children, and neonates with suspected or confirmed COVID-19 can be found in Considerations for Patients Treated with ACE Inhibitors and ARBs background for the clinical interest on use of renin-angiotensin-aldosterone (RAAS) antagonists (angiotensin-converting

2020 DynaMed Plus

72. COVID-19 and Patients With Cancer

(MPNs) for patients with MPNs patients with MPN who are on aspirin alone, blood thinning tablets (warfarin, apixaban, rivaroxaban), venesection alone, or no treatment are not considered at high risk for COVID-19 patients > 70 years old with MPN, or any patient with MPN and additional comorbidities such as heart disease, high blood pressure, or diabetes, are considered more high risk unclear risk for patients < 70 years old on medication to control blood count or MPN (such as hydroxycarbamide (...) , interferon, anagrelide, busulfan, or combination) patients taking ruxolitinib may be at higher risk for COVID-19 patients should continue on their medication to keep control of MPN no current evidence for aspirin worsening COVID-19 Reference - United Kingdom Myeloma Forum Guidance for COVID-19 and Multiple Myeloma Patients for newly diagnosed patients with multiple myeloma with CRAB criteria (hyper c alcemia, R enal insufficiency, A nemia, b one lesions) offer primary treatment, since untreated newly

2020 DynaMed Plus

73. Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence

. Search Strategy – Effectiveness Review Database: PubMed #1 "Hypertension"[Mesh] OR "Blood Pressure"[Mesh] OR "Hypercholesterolemia"[Mesh] OR "Cholesterol"[Mesh] OR "Aspirin"[Mesh] OR "hypertension"[Title/Abstract] OR "blood pressure"[Title/Abstract] OR "cholesterol"[Title/Abstract] OR "hypercholesterol"[Title/Abstract] OR "hypercholesterolemia"[Title/Abstract] OR “acetylsalicylic acid”[Title/Abstract] or “ASA”[Title/Abstract] OR “aspirin"[Title/Abstract] OR "high blood pressure" OR "high cholesterol (...) disease).mp. 36. (thromboembolic disease or congestive heart failure or atherosclerosis).mp. 37. or/28-36 38. 8 and 21 and 22 and 27 39. 7 and 21 and 22 and 27 and 37 40. limit 38 to english language 41. limit 39 to english language 42. 40 or 41 Database: Scopus #1 TITLE-ABS-KEY ( "Hypertension" OR "Blood Pressure" OR "Cholesterol" OR " hypercholesterol*” OR "aspirin" OR “acetylsalicylic acid” or “ASA” OR "high lipid levels" OR "high level lipids" OR "blood fat" OR "blood fats" OR "blood lipid

2020 Community Preventive Services Task Force

74. Evidence Brief: Capnography for Moderate Sedation in Non-Anesthesia Settings

the prospective observational study 15 indicating patients experienced more discomfort with capnography than routine monitoring. The high rates of false alarms in these studies align with clinicians’ anecdotal accounts of their experiences using capnography monitoring 14,32 – specifically, that false alarms have the potential to lead to “needless disruption, prolongation, or abandonment of procedures that the sedation was intended to facilitate.” 14,32 Tellingly, the ASA revised its Standards for Basic (...) . This could have resulted in missing eligible studies or data, although we made attempts to reduce this risk by establishing explicit inclusion criteria for studies and developing and using a piloted data abstraction tool. In terms of primary study limitations, most studies excluded those at highest risk of respiratory event (ASA category IV or V). In practice, those with ASA IV/V or other comorbidities that put them at higher risk would be referred to an anesthesiologist rather than undergo moderate

2020 Veterans Affairs Evidence-based Synthesis Program Reports

75. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. (Abstract)

Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Crohn's disease (CD) is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. 5-Aminosalicylates (5-ASAs) are locally acting, anti-inflammatory compounds that reduce inflammation of the colonic mucosa with release profiles that vary among various commercially available formulations. This updated Cochrane review summarizes current evidence on the use of 5-ASA (...) formulations for maintenance of surgically-induced remission in CD.To assess the efficacy and safety of 5-ASA agents for the maintenance of surgically-induced remission in CD.We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register from inception to 16 July 2018. We also searched references, conference abstracts, and trials registers.Randomised controlled trials (RCTs) that included participants with CD in remission following surgery and compared 5-ASAs to no treatment, placebo

2019 Cochrane Controlled trial quality: predicted high

76. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Full Text available with Trip Pro

of AZA or 6-MP for maintaining postoperative clinical remission compared to 5-ASA compounds was low. At 12 to 24 months , 64% (113/177) of purine analogue participants relapsed compared to 59% (101/170) of 5-ASA participants (RR 1.05; 95% CI 0.89 to 1.24; 347 participants; 4 studies; I² = 8%; low certainty evidence). The certainty of evidence that purine analogues are inferior for preventing postsurgical clinical relapse compared to tumour necrosis factor alpha agents (anti-TNF-α) was very low. At 12 (...) 1.36; 95% CI 0.57 to 3.27; 168 participants; 2 studies; I² = 0%; low certainty evidence). The effect of purine analogues on AEs compared to 5-ASA agents was uncertain. After 12 to 24 months, 41% (73/176) of purine analogue participants had an AE compared to 47% (81/171) of 5-ASA participants (RR 0.89; 95% CI 0.74 to 1.07; 346 participants; 4 studies; I² = 15%; low certainty evidence). The effect of purine analogues on AEs in comparison to anti TNF-α agents was uncertain. At 12 to 24 months, 57% (32

2019 Cochrane Controlled trial quality: predicted high

77. TNF-α blockers for the treatment of Kawasaki disease in children. (Abstract)

TNF-α blockers for the treatment of Kawasaki disease in children. Kawasaki disease (KD) is an acute inflammatory vasculitis (inflammation of the blood vessels) that mainly affects children between six months and five years of age. The vasculitis primarily impacts medium-sized blood vessels, especially in the coronary arteries. In most children, intravenous immunoglobulin (IVIG) and aspirin therapy rapidly reduce inflammatory markers, fever, and other clinical symptoms. However, approximately 15

2019 Cochrane

78. [SHINSA]English Translation of Review Report: Zagallo

"Kitasato Daiichi Sankyo" adsorbed cell culture-derived influenza vaccine (H5N1) March 2016 Adsorbed Influenza Vaccine (H5N1) "HOKKEN" adsorbed influenza vaccine (H5N1) October 2007 Adsorbed Influenza Vaccine (H5N1) "BIKEN" adsorbed influenza vaccine (H5N1) October 2007 Adynovate rurioctocog alfa pegol (genetical recombination) March 2016 Alabel/Alaglio aminolevulinic acid hydrochloride March 2013 Alecensa alectinib hydrochloride July 2014 Allergen Scratch Extract Positive control "TORII" Histamine (...) 2015 Sunvepra asunaprevir July 2014 Symproic naldemedine tosilate March 2017 Synflorix pneumococcal 10-valent conjugate vaccine adsorbed (non-typeable haemophilus influenzae [NTHi] protein D, diphtheria or tetanus toxoid conjugates) March 2015 T Name Active Ingredient Approved In PDF EN PDF JP Tafinlar dabrafenib mesilate March 2016 Tagrisso osimertinib mesilate March 2016 Takecab vonoprazan fumarate December 2014 Takelda aspirin/lansoprazole March 2014 Talion bepotastine besilate May 2015 Taltz

2019 Pharmaceuticals and Medical Devices Agency, Japan

79. Expansion of MBS item 73325 to include additional populations and mutations beyond those currently specified (for the characterisation of JAK2 or MPL genes)

of myeloproliferative disorders (Figure 1). Figure 1 Diagnostic workup of myeloproliferative disorders Source: Contracted Assessment for MSAC Application 1532. Figure A6.1 p, 14. The CA stated that treatment for PV, ET and PMF is based upon the patient’s risk. In ET, patients aged over 60 years with JAK2 mutations are considered at high risk, and are recommended for treatment with cytoreductive therapy if response to aspirin, hydroxyurea, interferons or anagrelide is inadequate. 7 9. Comparator The CA provided

2019 Medical Services Advisory Committee

80. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

of special interest ASA Acetylsalicylic acid ATC Anatomical Therapeutic Chemical [classification system] ATMP Advanced therapy medicinal product BF Biologic failure BID Twice daily CD Crohn’s disease CI Confidence interval CrI Credible interval CRP C-reactive protein CSR Clinical study report CTR Clinical trial register DIC Deviance information criterion ECCO European Crohn's and Colitis Organisation EL Evidence level EMA European Medicines Agency EOW Every other week EQ-5D EuroQol Questionnaire 5 (...) , left-sided or extensive colitis), previous medications and the course of the disease. The ultimate goal of UC treatment is to induce and then maintain remission and to reduce the risk of long-term complications and surgery. Medications used to treat UC include: aminosalicylates (5- ASAs), corticosteroids, immune modifiers (immunomodulators), biologics, and over-the-counter medications such as antidiarrhoeal agents and analgesics. Despite better treatment options, long- term colectomy rates have

2020 EUnetHTA

Systematic Reviews (Non-Premium)

Systematic reviews are arguably the most important way of telling if an intervention is worthwhile.  As a FREE user you have access to 100,000 less systematic reviews than a Pro user.  Upgrade today.